Lyra therapeutics reports first quarter 2022 financial results and provides corporate update

In april 2022, secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024 pivotal enlighten phase 3 clinical program and beacon phase 2 clinical trial targeting a broad spectrum of crs patients actively recruiting patients watertown, mass. , may 10, 2022 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, today reported financial results for the first quarter ended march 31, 2022, and highlighted recent accomplishments.
LYRA Ratings Summary
LYRA Quant Ranking